Abbott Libre Duo 10 Day: FDA authorized glucose-ketone specs

September 26, 2026

Medical Update Online USA

Overview

Abbott has received De Novo authorization from the FDA for its Libre Duo 10 Day system, making it the world’s first dual continuous glucose-ketone monitoring (CGK) system. This biowearable provides real-time glucose insights while also alerting diabetes patients to rising ketone levels, a critical feature for preventing diabetic ketoacidosis (DKA). Meeting both iCGM and new iCGK standards, its U.S. launch is anticipated later this year, potentially revolutionizing proactive diabetes management.

In Depth

Key Findings

Abbott has achieved a landmark De Novo authorization from the U.S. Food and Drug Administration (FDA) for its Libre Duo 10 Day system, establishing it as the world’s first dual continuous glucose-ketone monitoring (CGK) system designed for individuals with diabetes. This groundbreaking biowearable is set to transform diabetes management by simultaneously providing real-time insights into both glucose and ketone levels, offering a critical early warning system for preventing potentially life-threatening diabetic ketoacidosis (DKA).

Technical & Clinical Details

The Libre Duo 10 Day system leverages Abbott’s established sensor technology, continuously monitoring both glucose and ketone levels for up to 10 days. The device is a discreet, minimally invasive wearable, designed for ease of use by patients. By providing simultaneous data on these two key metabolic biomarkers, users gain a more comprehensive understanding of how diet, exercise, and medication impact their metabolic health. Early detection of rising ketone levels is paramount, as it can indicate the onset of DKA, enabling timely intervention and preventing severe complications. The system not only adheres to established integrated continuous glucose monitoring (iCGM) standards but also meets the newly introduced stringent performance criteria for integrated continuous glucose and ketone monitoring (iCGK).

Background & Context

Historically, diabetes management has focused predominantly on glucose monitoring, with ketone assessment largely reserved for manual, reactive testing during hyperglycemic emergencies. DKA, a severe complication resulting from excessive ketone production due to insulin deficiency, poses a significant risk, particularly for Type 1 diabetes patients. The introduction of Libre Duo 10 Day represents a paradigm shift, offering the first integrated solution for continuous tracking of both critical metabolic indicators within a single device. This provides patients with a more holistic view of their health and empowers them to engage in more proactive disease management.

Strategic Significance & Outlook

Following its success in European markets where it has already received CE Mark approval, Abbott plans to launch Libre Duo 10 Day in the U.S. later this year, expanding its global reach to more diabetes patients. This device will equip healthcare providers with richer datasets for optimizing patient treatment plans and enable patients to make more informed lifestyle choices. The broader implication is the potential for such integrated biosensors to be applied to a wider spectrum of metabolic and chronic disease monitoring, driving advancements in personalized health management and preventative care globally.

Source: https://medicalupdateonline.com/2026/09/fda-authorizes-libre-duo-10-day-worlds-first-dual-continuous-glucose-ketone-monitoring-system-for-people-with-diabetes-abbott/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.